Vor Biopharma (VOR) AI Stock Analysis

• Market Cap: $103.13M
• Dividend Yield: N/A
• Average Volume (3M): 354.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: 12.32%
• Country: US
• Employees: 168
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 124,780,785
• 10 Day Avg. Volume: 246,300
• 30 Day Avg. Volume: 354,676
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.67
• Price Target Upside: 920.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Vor Biopharma faces severe financial challenges with no revenue and ongoing losses, contributing to a low overall score. Technical analysis indicates weak momentum, further impacting the score negatively. Although recent corporate developments, including new funding and strategic appointments, offer some optimism, they are insufficient to mitigate the high financial risks and negative technical indicators.

Positive Factors

Clinical Trials

FDA does not require additional data to start the Phase III trial and agreed with VOR on its design.

Financial Performance

Vor Biopharma addressed the cash overhang with a $56M PIPE, extending the runway to YE25.

Safety and Efficacy

Safety profile is viewed positively as hepatobiliary adverse events were primarily grade 1/2 and hematologic adverse events were low.

Negative Factors

Share Dilution

Lower DCF-derived price target to $6 from $12, following the transaction, due to the growth in outstanding shares.

Vor Biopharma Business Overview & Revenue Model

Company Description

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

How the Company Makes Money

Vor Biopharma generates revenue primarily through research and development collaborations, partnerships, and potential future product sales. The company's business model is centered around developing its pipeline of eHSC-based therapies, which are designed to improve the efficacy and safety of existing cancer treatments. Revenue streams may include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies, as well as potential licensing agreements for its proprietary technologies. Additionally, Vor Biopharma may secure funding through government grants or research institutions to support its innovative research initiatives.

Vor Biopharma Financial Statement Overview

Summary

Vor Biopharma is in a critical growth phase with recent revenue generation. Despite strong gross margins, profitability is a significant issue due to continued high losses and negative cash flows. The company maintains solid liquidity and a manageable debt level, but the negative return on equity and challenges in achieving sustainable profitability are concerning.

Income Statement

Vor Biopharma has shown considerable revenue growth in the TTM with total revenue reaching $12.2 million from zero in previous years, marking a new phase of operations. However, the company is still facing substantial losses with a net income of -$112.5 million in the TTM and an EBIT of -$118 million, which reflects high operational costs and low profitability margins. The gross profit margin is positive at 77.6% due to the low cost of goods sold, but the net profit margin remains severely negative at -920.1%, highlighting ongoing financial challenges.

Balance Sheet

The balance sheet indicates a moderate debt-to-equity ratio of 0.45, suggesting a manageable level of debt. The equity ratio stands at 62.9%, showing a relatively healthy proportion of assets financed by equity. Return on equity is negative at -154.2%, reflecting the company's inability to generate positive returns on shareholders' investments due to consistent losses. The company maintains a strong cash position with cash and short-term investments of $62.8 million, which supports its liquidity.

Cash Flow

Operating cash flow remains negative at -$99.6 million, indicative of ongoing cash burn. The free cash flow is also negative at -$99.9 million, signaling cash flow challenges. On the positive side, free cash flow to net income ratio is close to 1, reflecting consistent cash outflows relative to reported net losses. However, the company has not shown growth in free cash flow, which remains a concern.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
12.23M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
9.49M	-3.49M	-8.96M	-4.45M	-1.39M	-91.00K
	EBIT
-118.00M	-126.04M	-93.42M	-69.02M	-43.37M	-10.42M
	EBITDA
-115.31M	-114.37M	-90.89M	-67.58M	-41.95M	-10.17M
	Net Income Common Stockholders
-112.46M	-117.86M	-90.77M	-68.78M	-43.34M	-11.45M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.47M	137.18M	230.25M	207.47M	48.54M	6.47M
	Total Assets
9.83M	198.13M	299.37M	242.59M	75.91M	9.83M
	Total Debt
0.00	35.66M	38.91M	18.01M	18.29M	0.00
	Net Debt
-6.47M	4.30M	-18.79M	-101.79M	-30.25M	-6.47M
	Total Liabilities
2.19M	47.40M	48.76M	26.33M	27.64M	2.19M
	Stockholders Equity
7.64M	150.72M	250.61M	216.26M	48.27M	7.64M
Cash Flow		Free Cash Flow
-99.89M	-101.36M	-93.61M	-73.04M	-40.45M	-10.60M
	Operating Cash Flow
-99.62M	-100.29M	-85.14M	-69.14M	-36.29M	-9.86M
	Investing Cash Flow
107.26M	71.01M	-94.09M	-91.65M	-4.16M	-748.00K
	Financing Cash Flow
131.00K	2.94M	117.14M	232.91M	82.53M	17.70M

Vor Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.24, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 17.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VOR.

Vor Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.96B	0.44	-53.15%	2.46%	21.42%	-0.68%
CRSP	46 Neutral	$3.51B	―	-19.20%	―	-89.95%	-123.71%
BLUE	42 Neutral	$38.38M	―	-270.20%	―	144.50%	-141.91%
FATE	42 Neutral	$105.49M	―	-54.21%	―	-78.55%	-0.92%
EDIT	39 Underperform	$109.11M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$951.33M	―	-54.00%	―	59.55%	3.09%
VOR	34 Underperform	$103.13M	―	-90.79%	―	―	12.32%

Vor Biopharma Corporate Events

Vor Biopharma Approves Stock Option Repricing Strategy

On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.

Vor Biopharma Strengthens Board with New Appointment

Vor Biopharma has appointed Erez Kalir, a seasoned investor and entrepreneur with deep experience in life sciences and technology, to its Board of Directors. This strategic appointment aligns with the company’s vision to advance its clinical programs and drive innovation in cancer treatment, potentially strengthening its market position and stakeholder confidence.

Vor Biopharma Secures $55.6M for Cancer Therapy Trials

Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical development and extend cash runway through 2025. The transaction involves significant stakeholders, including Reid Hoffman and RA Capital Management, and is expected to bolster Vor Bio’s efforts in advancing its clinical trials for cancer therapies, with updated data announcements anticipated in 2025.